Company intelligence / Profile preview

CH Trading Group

USA

Ownership: Private
Development stage: Other

Overview

In 2022, CH Trading Group signed a five-year, $225M minimum purchase agreement to distribute Celularity's Halal-certified regenerative biomaterial products to over 100 countries across the Middle East, North Africa, and Islamic markets.

Therapeutic areas: Dermatology
Modalities: Regenerative biomaterialBiologic
Industry: Surgical Medical Devices

Partnerships

Celularity (exclusive distributor of Halal-certified biomaterial products for 100+ Islamic market countries)

Beyond the preview

Go deeper on CH Trading Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH Trading Group.

Explore the full profile